IFPMA Statement on the launch of a new global collaboration to accelerate the development, production and equitable access to new COVID-19 tools
The biopharmaceutical industry is acutely aware of the enormous responsibility we have to patients and society to engage in unprecedented levels of collaboration to find a solution to COVID-19.
We stand ready to bring to this partnership our unique knowledge and expertise in the discovery and development of medicines and vaccines, as well as our experience building manufacturing capacity and distribution networks.
Today, scientists in the public and private sector hold the keys to our common goal: The swift end of the COVID-19 pandemic. We are proud to be part of this landmark global partnership and are fully committed to its goal to accelerate development, production and equitable global access to safe, quality, effective, and affordable COVID-19 therapeutics and vaccines.
In the fight against COVID-19, we must ensure that no one is left behind. We will only succeed in this journey together.
Statement delivered by: Thomas Cueni, Director General, IFPMA
Resources:
- Access to COVID-19 Tools (act) Accelerator
- IFPMA News Release: Pharma industry body joins as founding partner a new global collaboration to accelerate the development, production and equitable access
to new COVID-19 tools - Global Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
Related news and resources
IFPMA Statement at the closing of the WTO Ministerial Conference in Abu Dhabi
On 1 March, at the end of the 13th WTO Ministerial Conference, IFPMA issued a statement.
Read moreFebruary 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
WTO Ministerial Conference in Abu Dhabi is an opportunity to strengthen trade and health agenda
On 23 February, ahead of the 13th WTO Ministerial Conference, IFPMA and member associations from 10 countries issued a joint statement calling on trade ministers to commit to a comprehensive trade and health agenda that will strengthen the innovation ecosystem, remove trade barriers, promote trade facilitation, strengthen regulatory systems, and address under-resourced healthcare infrastructure.
Read more